Article Text
Statistics from Altmetric.com
QUESTION: In patients with no history of coronary artery disease (CAD), does a lipid lowering drug (cholestyramine, gemfibrozil, pravastatin, or lovastatin) decrease the risk for CAD events, CAD mortality, or all cause mortality?
Data sources
English language studies were identified by searching Medline (1994 to June 1999) with the Medical Subject Headings (MeSH) hyperlidemia and anti cholesterolemic agents and with MeSH or keywords identifying randomised controlled trials and individual drug names, the Cochrane Clinical Trials Registry, and bibliographies of systematic reviews and clinical practice guidelines.
Study selection
Randomised controlled trials were selected if they had ≥1 year of duration and measured CAD events, CAD mortality, and all cause mortality. Exclusion criteria were studies of secondary prevention or studies published in abstract form …